This guideline offers recommendations on the diagnosis, treatment and health promotion principles needed for the effective management of gonorrhoea. It is an update of the 2018 guideline.
MigchelsenSJEdneyJO’BrienN, et al.Sexually transmitted infections and screening for chlamydia in England, 2023. London: UK Health Security Agency, 2024.
2.
HandsfieldHH. Gonorrhea and uncomplicated gonococcal infection. In: HolmesKKMardhPASparlingPF, et al. (eds). Sexually transmitted diseases. New York: McGraw–Hill Co, 1984, pp. 205–219.
3.
CharlesonFTranJKolobaricA, et al.A systematic review of kissing as a risk factor for oropharyngeal gonorrhea or chlamydia. Sex Transm Dis2023; 50(7): 395–401.
4.
ChowEPFCornelisseVJReadTRH, et al.Saliva use as a lubricant for anal sex is a risk factor for rectal gonorrhoea among men who have sex with men, a new public health message: a cross-sectional survey. Sex Transm Infect2016; 92(7): 532–536.
5.
UnemoMLahraMMEscherM, et al.WHO global antimicrobial resistance surveillance for Neisseria gonorrhoeae 2017-18: a retrospective observational study. Lancet Microbe2021; 2(11): e627–e636.
6.
LahraMMMartinIDemczukW, et al.Cooperative recognition of internationally disseminated ceftriaxone-resistant Neisseria gonorrhoeae strain. Emerg Infect Dis2018; 24(4): 735–740.
7.
UKHSA. GRASP report: data to August 2024: UK Health Security Agency, 2024.
DayMPittRModyN, et al.Detection of 10 cases of ceftriaxone-resistant Neisseria gonorrhoeae in the United Kingdom, december 2021 to June 2022. Euro Surveill2022; 27(46): 2200803.
10.
FiferHDoumithMRubinsteinL, et al.Ceftriaxone-resistant Neisseria gonorrhoeae detected in England, 2015-24: an observational analysis. J Antimicrob Chemother2024; 79: 3332–3339.
11.
BarlowDPhillipsI. Gonorrhoea in women. Diagnostic, clinical, and laboratory aspects. Lancet1978; 1(8067): 761–764.
12.
LewisDABondMButtKD, et al.A one-year survey of gonococcal infection seen in the genitourinary medicine department of a London district general hospital. Int J STD AIDS1999; 10(9): 588–594.
13.
SherrardJBarlowD. Gonorrhoea in men: clinical and diagnostic aspects. Genitourin Med1996; 72(6): 422–426.
14.
LauAKongFYSHustonW, et al.Factors associated with anorectal Chlamydia trachomatis or Neisseria gonorrhoeae test positivity in women: a systematic review and meta-analysis. Sex Transm Infect2019; 95(5): 361–367.
15.
RichardsonDPickeringATrotmanD, et al.Pharyngeal gonorrhoea in men who have sex with men. Int J STD AIDS2021; 32(5): 449–452.
16.
MorrisGCStewartCMSchoemanSA, et al.A cross-sectional study showing differences in the clinical diagnosis of pelvic inflammatory disease according to the experience of clinicians: implications for training and audit. Sex Transm Infect2014; 90(6): 445–451.
17.
BleichATSheffieldJSWendelGDJr., et al.Disseminated gonococcal infection in women. Obstet Gynecol2012; 119(3): 597–602.
18.
LeeMHByunJJungM, et al.Disseminated gonococcal infection presenting as bacteremia and liver abscesses in a healthy adult. Infect Chemother2015; 47(1): 60–63.
WorkowskiKABolanGACenters for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep2015; 64(RR-03): 1–137.
21.
TangECJohnsonKAAlvaradoL, et al.Characterizing the rise of disseminated gonococcal infections in California, July 2020-July 2021. Clin Infect Dis2023; 76(2): 194–200.
22.
MoussiegtAFrançoisCBelmonteO, et al.Gonococcal arthritis: case series of 58 hospital cases. Clin Rheumatol2022; 41(9): 2855–2862.
23.
BirrellJMGunathilakeMSingletonS, et al.Characteristics and impact of disseminated gonococcal infection in the “Top End” of Australia. Am J Trop Med Hyg2019; 101(4): 753–760.
24.
BristoweHDayMFiferH, et al.Gonococcal pericarditis with tamponade - use of molecular technology to improve diagnosis and management. Int J Infect Dis2023; 134: 150–152.
25.
JainSWinHNChalamV, et al.Disseminated gonococcal infection presenting as vasculitis: a case report. J Clin Pathol2007; 60(1): 90–91.
26.
BelkacemACaumesEOuanichJ, et al.Changing patterns of disseminated gonococcal infection in France: cross-sectional data 2009-2011. Sex Transm Infect2013; 89(8): 613–615.
27.
EdwardsJLApicellaMA. The molecular mechanisms used by Neisseria gonorrhoeae to initiate infection differ between men and women. Clin Microbiol Rev2004; 17(4): 965–981.
28.
BelgaSGratrixJSmyczekP, et al.Gonococcal conjunctivitis in adults: case report and retrospective review of cases in Alberta, Canada, 2000-2016. Sex Transm Dis2019; 46(1): 47–51.
29.
Cuesta ChascoGCarreras-CastanerXZboromyrskaY, et al.Adult gonococcal conjunctivitis: prevalence, clinical features and complications. J Med Microbiol2021; 70(9). doi:10.1099/jmm.0.001416.
30.
KawashimaMKawakitaTDenS, et al.Surgical management of corneal perforation secondary to gonococcal keratoconjunctivitis. Eye (Lond)2009; 23(2): 339–344.
31.
BadashAGrennanDAlbrechtJ. Sexually transmitted diseases and HIV in transgender patients. Clin Dermatol2024; 42(2): 180–191.
32.
BodsworthNJPriceRDaviesSC. Gonococcal infection of the neovagina in a male-to-female transsexual. Sex Transm Dis1994; 21(4): 211–212.
33.
Van der SluisWBBoumanMBGijsL, et al.Gonorrhoea of the sigmoid neovagina in a male-to-female transgender. Int J STD AIDS2015; 26(8): 595–598.
34.
PHE. Guidance for the detection of gonorrhoea in England: Public Health England, 2021.
35.
CookRLHutchisonSLØstergaardL, et al.Systematic review: noninvasive testing for Chlamydia trachomatis and Neisseria gonorrhoeae. Ann Intern Med2005; 142(11): 914–925.
36.
Van DyckEIevenMPattynS, et al.Detection of Chlamydia trachomatis and Neisseria gonorrhoeae by enzyme immunoassay, culture, and three nucleic acid amplification tests. J Clin Microbiol2001; 39(5): 1751–1756.
37.
WhileyDMGarlandSMHarnettG, et al.Exploring ‘best practice’ for nucleic acid detection of Neisseria gonorrhoeae. Sex Health2008; 5(1): 17–23.
38.
MallikADasNMukherjeeS, et al.A systematic review and meta-analysis of different diagnostic procedures to detect gonococcus infection in resource-limited scenario. Indian J Med Microbiol2020; 38(3 & 4): 299–306.
39.
MensforthSThorleyNRadcliffeK. Auditing the use and assessing the clinical utility of microscopy as a point-of-care test for Neisseria gonorrhoeae in a sexual health clinic. Int J STD AIDS2018; 29(2): 157–163.
40.
ThorleyNRadcliffeK. The performance and clinical utility of cervical microscopy for the diagnosis of gonorrhoea in women in the era of the NAAT. Int J STD AIDS2015; 26(9): 656–660.
41.
GroverDPrimeKPPrinceMV, et al.Rectal gonorrhoea in men – is microscopy still a useful tool?Int J STD AIDS2006; 17(4): 277–279.
42.
ForniJMilesKHamillM. Microscopy detection of rectal gonorrhoea in asymptomatic men. Int J STD AIDS2009; 20(11): 797–798.
43.
CornelisseVJChowEPHuffamS, et al.Increased detection of pharyngeal and rectal gonorrhea in men who have sex with men after transition from culture to nucleic acid amplification testing. Sex Transm Dis2017; 44(2): 114–117.
44.
GaydosCAVan Der PolBJett-GoheenM, et al.Performance of the Cepheid CT/NG Xpert rapid PCR test for detection of Chlamydia trachomatis and Neisseria gonorrhoeae. J Clin Microbiol2013; 51(6): 1666–1672.
45.
LevyVBlackmoreCSKlausnerJD. Self-collection of specimens for nucleic acid-based diagnosis of pharyngeal, cervicovaginal, urethral, and rectal Neisseria gonorrhoeae and Chlamydia trachomatis infections. Methods Mol Biol2012; 903: 407–418.
46.
GeelenTHRossenJWBeerensAM, et al.Performance of cobas(R) 4800 and m2000 real-time assays for detection of Chlamydia trachomatis and Neisseria gonorrhoeae in rectal and self-collected vaginal specimen. Diagn Microbiol Infect Dis2013; 77(2): 101–105.
47.
Van Der PolBHookEW3rdWilliamsJA, et al.Performance of the BD CTQx and GCQx amplified assays on the BD Viper LT compared with the BD Viper XTR system. Sex Transm Dis2015; 42(9): 521–523.
48.
FootmanADionne-OdomJAaronKJ, et al.Performance of 4 molecular assays for detection of chlamydia and gonorrhea in a sample of human immunodeficiency virus-positive men who have sex with men. Sex Transm Dis2020; 47(3): 158–161.
49.
PalmerHMMallinsonHWoodRL, et al.Evaluation of the specificities of five DNA amplification methods for the detection of Neisseria gonorrhoeae. J Clin Microbiol2003; 41(2): 835–837.
50.
PopeCFHayPAlexanderS, et al.Positive predictive value of the Becton Dickinson VIPER system and the ProbeTec GC Q x assay, in extracted mode, for detection of Neisseria gonorrhoeae. Sex Transm Infect2010; 86(6): 465–469.
51.
DoernbergSBKomarowLTranTTT, et al.Simultaneous evaluation of diagnostic assays for pharyngeal and rectal Neisseria gonorrhoeae and Chlamydia trachomatis using a master protocol. Clin Infect Dis2020; 71(9): 2314–2322.
52.
CherneskyMAMartinDHHookEW, et al.Ability of new APTIMA CT and APTIMA GC assays to detect Chlamydia trachomatis and Neisseria gonorrhoeae in male urine and urethral swabs. J Clin Microbiol2005; 43(1): 127–131.
53.
AaronKJGrinerSFootmanA, et al.Vaginal swab vs urine for detection of Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis: a meta-analysis. Ann Fam Med2023; 21(2): 172–179.
54.
SchachterJCherneskyMAWillisDE, et al.Vaginal swabs are the specimens of choice when screening for Chlamydia trachomatis and Neisseria gonorrhoeae: results from a multicenter evaluation of the APTIMA assays for both infections. Sex Transm Dis2005; 32(12): 725–728.
55.
StewartCMSchoemanSABoothRA, et al.Assessment of self taken swabs versus clinician taken swab cultures for diagnosing gonorrhoea in women: single centre, diagnostic accuracy study. BMJ2012; 345: e8107.
56.
Van Der PolBTaylorSNLiesenfeldO, et al.Vaginal swabs are the optimal specimen for detection of genital Chlamydia trachomatis or Neisseria gonorrhoeae using the Cobas 4800 CT/NG test. Sex Transm Dis2013; 40(3): 247–250.
57.
BennPDRooneyGCarderC, et al.Chlamydia trachomatis and Neisseria gonorrhoeae infection and the sexual behaviour of men who have sex with men. Sex Transm Infect2007; 83(2): 106–112.
58.
LavelleSJJonesKEMallinsonH, et al.Finding, confirming, and managing gonorrhoea in a population screened for chlamydia using the Gen-Probe Aptima Combo2 assay. Sex Transm Infect2006; 82(3): 221–224.
59.
PondMJHallCLMiariVF, et al.Accurate detection of Neisseria gonorrhoeae ciprofloxacin susceptibility directly from genital and extragenital clinical samples: towards genotype-guided antimicrobial therapy. J Antimicrob Chemother2016; 71(4): 897–902.
60.
van LiereGDukers-MuijrersNKuizenga-WesselS, et al.Routine universal testing versus selective or incidental testing for oropharyngeal Neisseria gonorrhoeae in women in The Netherlands: a retrospective cohort study. Lancet Infect Dis2021; 21(6): 858–867.
61.
McLaughlinSEGoldenMRSogeOO, et al.Pharyngeal gonorrhea in heterosexual male and female sex partners of persons with gonorrhea. Sex Transm Dis2023; 50(4): 203–208.
62.
EyreDWSandersonNDLordE, et al.Gonorrhoea treatment failure caused by a Neisseria gonorrhoeae strain with combined ceftriaxone and high-level azithromycin resistance, England, February 2018. Euro Surveill2018; 23(27): 1800323.
63.
FiferHNatarajanUJonesL, et al.Failure of dual antimicrobial therapy in treatment of gonorrhea. N Engl J Med2016; 374(25): 2504–2506.
64.
MoranJS. Treating uncomplicated Neisseria gonorrhoeae infections: is the anatomic site of infection important?Sex Transm Dis1995; 22(1): 39–47.
65.
MoranJSLevineWC. Drugs of choice for the treatment of uncomplicated gonococcal infections. Clin Infect Dis1995; 20(Suppl 1): S47–S65.
66.
HuxtaRASoniyiOHalbritterA, et al.Extragenital screening of Chlamydia trachomatis and Neisseria gonorrhoeae among women in the college health setting. Sex Transm Dis2021; 48(9): 643–647.
67.
van LiereGDukers-MuijrersNLevelsL, et al.High proportion of anorectal Chlamydia trachomatis and Neisseria gonorrhoeae after routine universal urogenital and anorectal screening in women visiting the sexually transmitted infection clinic. Clin Infect Dis2017; 64(12): 1705–1710.
68.
van LiereGHoebeCJNiekampAM, et al.Standard symptom- and sexual history-based testing misses anorectal Chlamydia trachomatis and Neisseria gonorrhoeae infections in swingers and men who have sex with men. Sex Transm Dis2013; 40(4): 285–289.
69.
ChowEPFBradshawCSWilliamsonDA, et al.Changing from Clinician-collected to self-collected throat swabs for oropharyngeal gonorrhea and chlamydia screening among men who have sex with men. J Clin Microbiol2020; 58(9): e01215.
70.
Dangerfield IiDTFarleyJEHoldenJ, et al.Acceptability of self-collecting oropharyngeal swabs for sexually transmissible infection testing among men and women. Sex Health2019; 16(3): 296–298.
71.
FreemanAHBernsteinKTKohnRP, et al.Evaluation of self-collected versus clinician-collected swabs for the detection of Chlamydia trachomatis and Neisseria gonorrhoeae pharyngeal infection among men who have sex with men. Sex Transm Dis2011; 38(11): 1036–1039.
72.
PittmanEPurcellHDizeL, et al.Acceptability and feasibility of self-sampling for the screening of sexually transmitted infections in cabana privacy shelters. Int J STD AIDS2018; 29(5): 461–465.
73.
WayalSLlewellynCSmithH, et al.Self-sampling for oropharyngeal and rectal specimens to screen for sexually transmitted infections: acceptability among men who have sex with men. Sex Transm Infect2009; 85(1): 60–64.
74.
BarbeeLAGoldenMRThibaultCS, et al.Performance of patient-collected specimens for Neisseria gonorrhoeae culture. Clin Infect Dis2021; 73(9): e3196–e3200.
75.
Brendefur CorwinLMCampbellPJakobsenK, et al.Improvement in Neisseria gonorrhoeae culture rates by bedside inoculation and incubation at a clinic for sexually transmitted infections. Ann Clin Microbiol Antimicrob2023; 22(1): 27.
76.
SultanBWhiteJAFishR, et al.The “3 in 1” study: pooling self-taken pharyngeal, urethral, and rectal samples into a single sample for analysis for detection of Neisseria gonorrhoeae and Chlamydia trachomatis in men who have sex with men. J Clin Microbiol2016; 54(3): 650–656.
77.
AlmeriaJPhamJParisKS, et al.Pooled 3-anatomic-site testing for Chlamydia trachomatis and Neisseria gonorrhoeae: a systematic review and meta-analysis. Sex Transm Dis2021; 48(12): e215–e222.
78.
BristowCCMorrisSRLittleSJ, et al.Meta-analysis of the Cepheid Xpert((R)) CT/NG assay for extragenital detection of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) infections. Sex Health2019; 16(4): 314–319.
79.
MorrisSRBristowCCWierzbickiMR, et al.Performance of a single-use, rapid, point-of-care PCR device for the detection of Neisseria gonorrhoeae, Chlamydia trachomatis, and Trichomonas vaginalis: a cross-sectional study. Lancet Infect Dis2021; 21(5): 668–676.
80.
Van Der PolBGaydosCA. A profile of the binx health io® molecular point-of-care test for chlamydia and gonorrhea in women and men. Expert Rev Mol Diagn2021; 21(9): 861–868.
81.
EbeyanSWindsorMBordinA, et al.Evaluation of the ResistancePlus GC (beta) assay: a commercial diagnostic test for the direct detection of ciprofloxacin susceptibility or resistance in Neisseria gonorrhoeae. J Antimicrob Chemother2019; 74(7): 1820–1824.
82.
LeeDYJAshcroftMMChowEPF, et al.Reflex detection of ciprofloxacin resistance in Neisseria gonorrhoeae by use of the SpeeDx resistancePlus GC assay. J Clin Microbiol2021; 59(5): e00089.
83.
ShimutaKTakahashiHAkedaY, et al.Loop-mediated isothermal amplification assay for identifying Neisseria gonorrhoeae nonmosaic penA-targeting strains potentially eradicable by cefixime. Microbiol Spectr2022; 10(5): e0233522.
84.
FiumaraNJAsvadiS. Asymptomatic gonococcal urethritis in a male transsexual female. Br J Vener Dis1978; 54(2): 130–131.
85.
HiransuthikulAJanamnuaysookRHimmaL, et al.Acceptability and satisfaction towards self-collection for chlamydia and gonorrhoea testing among transgender women in Tangerine Clinic, Thailand: shifting towards the new normal. J Int AIDS Soc2021; 24(9): e25801.
86.
AokiTMizushimaDTakanoM, et al.Efficacy of 1 g ceftriaxone monotherapy compared to dual therapy with azithromycin or doxycycline for treating extragenital gonorrhea among men who have sex with men. Clin Infect Dis2021; 73(8): 1452–1458.
87.
BelakebiDGodreuilSPicotMC, et al.Response rate to intramuscular ceftriaxone 1 g in patients with gonococcal infection: a French monocentric prospective study. J Eur Acad Dermatol Venereol2023; 37(10): e1229–e1231.
88.
de VriesHJCde LaatMJongenVW, et al.Efficacy of ertapenem, gentamicin, fosfomycin, and ceftriaxone for the treatment of anogenital gonorrhoea (NABOGO): a randomised, non-inferiority trial. Lancet Infect Dis2022; 22(5): 706–717.
89.
LoFWYKongFYSHockingJS. Treatment efficacy for rectal Neisseria gonorrhoeae: a systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother2021; 76(12): 3111–3124.
90.
KongFYSHatzisCLLauA, et al.Treatment efficacy for pharyngeal Neisseria gonorrhoeae: a systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother2020; 75(11): 3109–3119.
91.
EyreDWTownKStreetT, et al.Detection in the United Kingdom of the Neisseria gonorrhoeae FC428 clone, with ceftriaxone resistance and intermediate resistance to azithromycin, October to December 2018. Euro Surveill2019; 24(10): 1900147.
92.
PichicheroMECaseyJR. Safe use of selected cephalosporins in penicillin-allergic patients: a meta-analysis. Otolaryngol Head Neck Surg2007; 136(3): 340–347.
OngJJAguirreIUnemoM, et al.Comparison of gastrointestinal side effects from different doses of azithromycin for the treatment of gonorrhoea. J Antimicrob Chemother2022; 77(7): 2011–2016.
95.
DeguchiTYasudaMYokoiS, et al.Treatment of uncomplicated gonococcal urethritis by double-dosing of 200 mg cefixime at a 6-h interval. J Infect Chemother2003; 9(1): 35–39.
96.
ChisholmSAMoutonJWLewisDA, et al.Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink?J Antimicrob Chemother2010; 65(10): 2141–2148.
97.
BarbeeLAKeraniRPDombrowskiJC, et al.A retrospective comparative study of 2-drug oral and intramuscular cephalosporin treatment regimens for pharyngeal gonorrhea. Clin Infect Dis2013; 56(11): 1539–1545.
98.
BizovaBProchazkaPNycovaE, et al.Single-dose cefixime 800 mg plus doxycycline 100 mg twice a day for 7 days compared with single-dose ceftriaxone 1 g plus single-dose azithromycin 2 g for treatment of urogenital, rectal, and pharyngeal gonorrhoea: a randomised clinical trial. Clin Microbiol Infect2024; 30(2): 211–215.
99.
IsonCAHusseyJSankarKN, et al.Gonorrhoea treatment failures to cefixime and azithromycin in England, 2010. Euro Surveill2011; 16(14): 19833.
100.
UnemoMGolparianDSyversenG, et al.Two cases of verified clinical failures using internationally recommended first-line cefixime for gonorrhoea treatment, Norway, 2010. Euro Surveill2010; 15(47): 19721.
101.
YangKJKojimaNBristowCC, et al.Effectiveness of cefixime for the treatment of Neisseria gonorrhoeae infection at 3 anatomic sites: a systematic review and meta-analysis. Sex Transm Dis2023; 50(3): 131–137.
102.
RossJDCBrittainCColeM, et al.Gentamicin compared with ceftriaxone for the treatment of gonorrhoea (G-ToG): a randomised non-inferiority trial. Lancet2019; 393(10190): 2511–2520.
103.
RobFKlubalováBNyčováE, et al.Gentamicin 240 mg plus azithromycin 2 g vs. ceftriaxone 500 mg plus azithromycin 2 g for treatment of rectal and pharyngeal gonorrhoea: a randomized controlled trial. Clin Microbiol Infect2020; 26(2): 207–212.
104.
BarbeeLASogeOOMorganJ, et al.Gentamicin alone is inadequate to eradicate Neisseria gonorrhoeae from the pharynx. Clin Infect Dis2020; 71(8): 1877–1882.
105.
ColeMJTanWFiferH, et al.Gentamicin, azithromycin and ceftriaxone in the treatment of gonorrhoea: the relationship between antibiotic MIC and clinical outcome. J Antimicrob Chemother2020; 75(2): 449–457.
106.
TapsallJWShultzTRLimniosEA, et al.Failure of azithromycin therapy in gonorrhea and discorrelation with laboratory test parameters. Sex Transm Dis1998; 25(10): 505–508.
107.
KlausnerJDBristowCCSogeOO, et al.Resistance-guided treatment of gonorrhea: a prospective clinical study. Clin Infect Dis2021; 73(2): 298–303.
108.
Allan-BlitzLTHumphriesRMHemarajataP, et al.Implementation of a rapid genotypic assay to promote targeted ciprofloxacin therapy of Neisseria gonorrhoeae in a large health system. Clin Infect Dis2017; 64(9): 1268–1270.
109.
BuonoSAWatsonTDBorensteinLA, et al.Stemming the tide of drug-resistant Neisseria gonorrhoeae: the need for an individualized approach to treatment. J Antimicrob Chemother2015; 70(2): 374–381.
110.
MilliganALRandagACLekkerkerkS, et al.Increased incidence of adult gonococcal keratoconjunctivitis at two tertiary eye hospitals in Western Europe: clinical features, complications and antimicrobial susceptibility. Br J Ophthalmol2024; 108: 788–792.
UllmanSRousselTJCulbertsonWW, et al.Neisseria gonorrhoeae keratoconjunctivitis. Ophthalmology1987; 94(5): 525–531.
113.
HaimoviciRRousselTJ. Treatment of gonococcal conjunctivitis with single-dose intramuscular ceftriaxone. Am J Ophthalmol1989; 107(5): 511–514.
114.
ECDC. Response plan to control and manage the threat of multi- and extensively drug-resistant gonorrhoea in Europe – 2019 update. Stockholm: European Centre for Disease Prevention and Control, 2019.
115.
PoncinTMerimecheMBrailleA, et al.Two cases of multidrug-resistant Neisseria gonorrhoeae related to travel in south-eastern Asia, France, June 2019. Euro Surveill2019; 24(36): 1900528.
116.
UnemoMGolparianDNicholasR, et al.High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob Agents Chemother2012; 56(3): 1273–1280.
117.
XuWQZhengXLLiuJW, et al.Antimicrobial susceptibility of ertapenem in Neisseria gonorrhoeae isolates collected within the China Gonococcal Resistance Surveillance Programme (China-GRSP) 2018. Infect Drug Resist2021; 14: 4183–4189.
118.
LiXLeWLouX, et al.In vitro activity of ertapenem against Neisseria gonorrhoeae clinical isolates with decreased susceptibility or resistance to extended-spectrum cephalosporins in Nanjing, China (2013 to 2019). Antimicrob Agents Chemother2022; 66(5): e0010922.
119.
CaveneeMRFarrisJRSpaldingTR, et al.Treatment of gonorrhea in pregnancy. Obstet Gynecol1993; 81(1): 33–38.
120.
Comunian-CarrascoGPena-MartiGEMarti-CarvajalAJ. Antibiotics for treating gonorrhoea in pregnancy. Cochrane Database Syst Rev2018; 2(2): CD011167.
121.
RamusRMSheffieldJSMayfieldJA, et al.A randomized trial that compared oral cefixime and intramuscular ceftriaxone for the treatment of gonorrhea in pregnancy. Am J Obstet Gynecol2001; 185(3): 629–632.
122.
ChowEPFMaddafordKHockingJS, et al.An open-label, parallel-group, randomised controlled trial of antiseptic mouthwash versus antibiotics for oropharyngeal gonorrhoea treatment (OMEGA2). Sci Rep2020; 10(1): 19386.
123.
Van DijckCTsoumanisADe HondtA, et al.Chlorhexidine mouthwash fails to eradicate oropharyngeal gonorrhea in a clinical pilot trial (MoNg). Sex Transm Dis2022; 49(2): e38–e41.
124.
ChowEPFWilliamsonDAHockingJS, et al.Antiseptic mouthwash for gonorrhoea prevention (OMEGA): a randomised, double-blind, parallel-group, multicentre trial. Lancet Infect Dis2021; 21(5): 647–656.
125.
JephcottAE. Microbiological diagnosis of gonorrhoea. Genitourin Med1997; 73(4): 245–252.
126.
WindCMSchim van der LoeffMFUnemoM, et al.Test of cure for anogenital gonorrhoea using modern RNA-based and DNA-based nucleic acid amplification tests: a prospective cohort study. Clin Infect Dis2016; 62(11): 1348–1355.
127.
BarbeeLASogeOOKhosropourCM, et al.Time to clearance of Neisseria gonorrhoeae RNA at the pharynx following treatment. J Clin Microbiol2022; 60(6): e0039922.
128.
MensforthSRadcliffeK. Is it time to reconsider epidemiological treatment for gonorrhoea?Int J STD AIDS2018; 29(10): 1043–1044.
129.
KohliMMedlandNFiferH, et al.BASHH updated position statement on doxycycline as prophylaxis for sexually transmitted infections. Sex Transm Infect2022; 98(3): 235–236.
